110 related articles for article (PubMed ID: 26374242)
1. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.
Potkonjak M; Miura JT; Turaga KK; Johnston FM; Tsai S; Christians KK; Gamblin TC
HPB (Oxford); 2015 Dec; 17(12):1119-23. PubMed ID: 26374242
[TBL] [Abstract][Full Text] [Related]
2. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.
Jarnagin WR; Klimstra DS; Hezel M; Gonen M; Fong Y; Roggin K; Cymes K; DeMatteo RP; D'Angelica M; Blumgart LH; Singh B
J Clin Oncol; 2006 Mar; 24(7):1152-60. PubMed ID: 16505435
[TBL] [Abstract][Full Text] [Related]
3. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.
Tanaka M; Shibahara J; Ishikawa S; Ushiku T; Morikawa T; Shinozaki-Ushiku A; Hayashi A; Misumi K; Tanaka A; Katoh H; Sakuma K; Kokudo T; Inagaki Y; Arita J; Sakamoto Y; Hasegawa K; Fukayama M
Virchows Arch; 2019 Jan; 474(1):39-46. PubMed ID: 30349952
[TBL] [Abstract][Full Text] [Related]
4. Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma".
Braxton DR; Saxe D; Damjanov N; Stashek K; Shroff S; Morrissette JD; Tondon R; Furth EE
Hum Pathol; 2017 Apr; 62():232-241. PubMed ID: 28232156
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Miura JT; Johnston FM; Thomas J; George B; Eastwood D; Tsai S; Christians KK; Turaga KK; Gamblin TC
J Surg Oncol; 2014 Sep; 110(3):302-6. PubMed ID: 24844210
[TBL] [Abstract][Full Text] [Related]
6. Time to move to targeted drugs in biliary tract cancer?
Louvet C; Tournigand C
Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
[No Abstract] [Full Text] [Related]
7. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels.
Surrey LF; Frank R; Zhang PJ; Furth EE
Am J Surg Pathol; 2014 Feb; 38(2):224-7. PubMed ID: 24418856
[TBL] [Abstract][Full Text] [Related]
8. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.
Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC
Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705
[TBL] [Abstract][Full Text] [Related]
9. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
10. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
11. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA
J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014
[TBL] [Abstract][Full Text] [Related]
12. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Subbiah IM; Subbiah V; Tsimberidou AM; Naing A; Kaseb AO; Javle M; Fu S; Hong DS; Piha-Paul S; Wheler JJ; Hess KR; Janku F; Falchook GS; Wolff RA; Kurzrock R
Oncotarget; 2013 Jan; 4(1):156-65. PubMed ID: 23391555
[TBL] [Abstract][Full Text] [Related]
14. Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma.
Brackett DG; Neyaz A; Arora K; Masia R; Mattia A; Zukerberg L; Misdraji J; Goyal L; Zhu AX; Ferrone CR; Yilmaz OH; Deshpande V
J Clin Pathol; 2020 Jan; 73(1):23-29. PubMed ID: 31422372
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.
Wakai T; Shirai Y; Sakata J; Takamura M; Matsuda Y; Korita PV; Muneoka K; Sasaki M; Ajioka Y; Hatakeyama K
Hepatogastroenterology; 2011; 58(110-111):1659-63. PubMed ID: 21940346
[TBL] [Abstract][Full Text] [Related]
16. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
[TBL] [Abstract][Full Text] [Related]
17. Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma.
Sur MD; In H; Sharpe SM; Baker MS; Weichselbaum RR; Talamonti MS; Posner MC
Ann Surg Oncol; 2015 Jul; 22(7):2209-17. PubMed ID: 25476031
[TBL] [Abstract][Full Text] [Related]
18. Sarcomatous cholangiocarcinoma.
Gupta K; Powari M; Dey P
Diagn Cytopathol; 2003 Mar; 28(3):168-9. PubMed ID: 12619101
[No Abstract] [Full Text] [Related]
19. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model.
Iguchi T; Yamashita N; Aishima S; Kuroda Y; Terashi T; Sugimachi K; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
Oncology; 2009; 76(4):293-300. PubMed ID: 19262069
[TBL] [Abstract][Full Text] [Related]
20. Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignancies.
Nishijima T; Nishina M; Fujiwara K
Jpn J Clin Oncol; 1997 Feb; 27(1):13-7. PubMed ID: 9070334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
